Targeted alpha-therapies (TATs) are emerging as powerful radiopharmaceutical tools for cancer treatment, allowing precise and localised dosing of highly potent radiotherapy. Growing interesting and positive findings from clinical trials demonstrate TAT to have the potential to be field disrupting and provide enhanced therapeutic outcomes. However, an underpinning mechanistic understanding of TAT behaviour and how the body responds to delivered therapy is required for this to be realized. The project will focus on establishing an understanding of the complex biological responses to radiotherapy in an effort to both predict therapeutic response using prognostic biomarkers, as well as develop a comprehensive understanding of the bodies immunological responses to radiation damage. Together this will allow us to develop refined therapeutic regimens as well as assist in harnessing the bodies own immune system for improved patient outcomes.